AXON Form 4: Director Jeri Williams Received 100 Shares on 08/29/2025
Jeri Williams, a director of Axon Enterprise, Inc. (AXON), received 100 restricted shares on 08/29/2025 that vested in full on the grant date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jeri Williams, a director of Axon Enterprise, Inc. (AXON), received 100 restricted shares on 08/29/2025 that vested in full on the grant date. The award was granted under the company’s Second Amended and Restated 2022 Stock Incentive Plan and carried a reported price of $0. After the transaction, Ms. Williams is reported to beneficially own 1,516 shares of Axon common stock on a direct basis. The Form 4 was signed on behalf of Ms. Williams by an attorney-in-fact on 09/03/2025.
Insights
TL;DR: Director received a small, fully vested equity grant, modestly increasing direct holdings; likely neutral for shareholders.
This Form 4 discloses a director-level issuance of 100 restricted shares that vested immediately. The grant was issued under Axon’s 2022 Stock Incentive Plan and reported at a $0 price, consistent with restricted stock unit settlement practices where shares are delivered without a purchase price at vesting. The director’s total direct beneficial ownership after the transaction is 1,516 shares. Given the small size of the grant relative to a public company’s outstanding shares, the transaction appears routine and not material to Axon’s capital structure or control.
TL;DR: Routine director equity compensation; transparency maintained through timely Form 4 filing.
The filing shows compliance with Section 16 reporting: the transaction date is 08/29/2025 and the Form 4 was executed by an attorney-in-fact on 09/03/2025. The disclosure identifies the award as restricted stock units under the company’s equity plan with immediate vesting. From a governance perspective, the recordkeeping and disclosure appear standard for executive/director compensation practices, and the immediate vesting should be understood as part of the specific grant terms rather than an ongoing scheduled vesting event.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 100 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents a grant of restricted stock units pursuant to the Axon Enterprise, Inc. Second Amended and Restated 2022 Stock Incentive Plan. The shares vested in full on the grant date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did AXON director Jeri Williams report on Form 4?
When was the Form 4 signed for the AXON filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.